File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Efficacy of dual vaccination of pandemic H1N1 2009 influenza and seasonal influenza on institutionalized elderly: a one-year prospective cohort study

TitleEfficacy of dual vaccination of pandemic H1N1 2009 influenza and seasonal influenza on institutionalized elderly: a one-year prospective cohort study
Authors
Issue Date2011
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
Citation
Vaccine, 2011, v. 29 n. 44, p. 7773-7778 How to Cite?
AbstractBACKGROUND: The influenza A (H1N1) 2009 pandemic was declared by the WHO in April 2009. In Hong Kong, the vaccination program began in December 2009 in addition to the annual seasonal trivalent influenza vaccination program. The clinical efficacy of dual vaccination was unknown. METHOD: From December 2009 to November 2010, a prospective 12-month cohort study on institutionalized elderly of nine nursing homes was conducted. Elderly persons who were followed up by the Hong Kong West Community Geriatric Assessment Team and had been vaccinated by the Department of Health were included. Outcome measures included all cause mortality, all cause hospitalization, hospitalization for fever on admission and hospitalization for pneumonia based on ICD-9-CM. RESULTS: 711 elderly persons were included. 274 received both seasonal influenza vaccine and (H1N1) 2009 vaccine (H1N1-TIV), 368 received seasonal influenza vaccine only (TIV alone) and 69 received no vaccination (unvaccinated). Baseline characteristics were well matched between the groups, except there were fewer females in the TIV alone. The 12-month mortality rates of the H1N1-TIV, TIV alone and unvaccinated were 10.6%, 19.8% and 29%, respectively. Multivariate analysis demonstrated that dual vaccination in the institutionalized elderly significantly reduced all cause mortality by 54% (Hazard Ratio [HR] 0.46; 95% confidence interval [CI] 0.29-0.72; p<0.001) and 74% (HR 0.26; CI 0.13-0.49; p<0.001), compared with vaccination of seasonal vaccination alone and no vaccination, respectively. Dual vaccination also reduced all cause hospitalization, hospitalization for fever on admission and hospitalization for pneumonia compared with seasonal vaccination alone and the unvaccinated group. CONCLUSION: Dual vaccination with both H1N1 and seasonal vaccinations provided additional protection to institutionalized elderly in reducing mortality and hospitalization.
Persistent Identifierhttp://hdl.handle.net/10722/157648
ISSN
2015 Impact Factor: 3.413
2015 SCImago Journal Rankings: 2.044
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChan, TCen_US
dc.contributor.authorHung, IFNen_US
dc.contributor.authorLuk, JKHen_US
dc.contributor.authorShea, YFen_US
dc.contributor.authorChan, FHWen_US
dc.contributor.authorWoo, PCYen_US
dc.contributor.authorChu, LWen_US
dc.date.accessioned2012-08-08T08:51:56Z-
dc.date.available2012-08-08T08:51:56Z-
dc.date.issued2011en_US
dc.identifier.citationVaccine, 2011, v. 29 n. 44, p. 7773-7778en_US
dc.identifier.issn0264-410Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/157648-
dc.description.abstractBACKGROUND: The influenza A (H1N1) 2009 pandemic was declared by the WHO in April 2009. In Hong Kong, the vaccination program began in December 2009 in addition to the annual seasonal trivalent influenza vaccination program. The clinical efficacy of dual vaccination was unknown. METHOD: From December 2009 to November 2010, a prospective 12-month cohort study on institutionalized elderly of nine nursing homes was conducted. Elderly persons who were followed up by the Hong Kong West Community Geriatric Assessment Team and had been vaccinated by the Department of Health were included. Outcome measures included all cause mortality, all cause hospitalization, hospitalization for fever on admission and hospitalization for pneumonia based on ICD-9-CM. RESULTS: 711 elderly persons were included. 274 received both seasonal influenza vaccine and (H1N1) 2009 vaccine (H1N1-TIV), 368 received seasonal influenza vaccine only (TIV alone) and 69 received no vaccination (unvaccinated). Baseline characteristics were well matched between the groups, except there were fewer females in the TIV alone. The 12-month mortality rates of the H1N1-TIV, TIV alone and unvaccinated were 10.6%, 19.8% and 29%, respectively. Multivariate analysis demonstrated that dual vaccination in the institutionalized elderly significantly reduced all cause mortality by 54% (Hazard Ratio [HR] 0.46; 95% confidence interval [CI] 0.29-0.72; p<0.001) and 74% (HR 0.26; CI 0.13-0.49; p<0.001), compared with vaccination of seasonal vaccination alone and no vaccination, respectively. Dual vaccination also reduced all cause hospitalization, hospitalization for fever on admission and hospitalization for pneumonia compared with seasonal vaccination alone and the unvaccinated group. CONCLUSION: Dual vaccination with both H1N1 and seasonal vaccinations provided additional protection to institutionalized elderly in reducing mortality and hospitalization.en_US
dc.languageengen_US
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccineen_US
dc.relation.ispartofVaccineen_US
dc.subject.meshHospitalization - statistics and numerical dataen_US
dc.subject.meshInfluenza Vaccines - administration and dosage - immunologyen_US
dc.subject.meshInfluenza, Human - mortality - prevention and controlen_US
dc.subject.meshInstitutionalizationen_US
dc.subject.meshVaccination - methodsen_US
dc.titleEfficacy of dual vaccination of pandemic H1N1 2009 influenza and seasonal influenza on institutionalized elderly: a one-year prospective cohort studyen_US
dc.typeArticleen_US
dc.identifier.emailChan, TC: tuenching@yahoo.com.hken_US
dc.identifier.emailHung, IFN: ivanhung@hkucc.hku.hken_US
dc.identifier.emailLuk, JKH: lukkh@ha.org.hk-
dc.identifier.emailShea, YF: elphashea@gmail.com-
dc.identifier.emailChan, FHW: fchan@ha.org.hk-
dc.identifier.emailWoo, PCY: pcywoo@hkucc.hku.hk-
dc.identifier.emailChu, LW: lwchu@hkucc.hku.hk-
dc.identifier.authorityHung, IFN=rp00508en_US
dc.identifier.authorityWoo, PCY=rp00430en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.vaccine.2011.07.112en_US
dc.identifier.pmid21821084-
dc.identifier.scopuseid_2-s2.0-80053593181en_US
dc.identifier.hkuros203199-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-80053593181&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume29en_US
dc.identifier.issue44en_US
dc.identifier.spage7773en_US
dc.identifier.epage7778en_US
dc.identifier.isiWOS:000296546900033-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridChu, LW=7202236665en_US
dc.identifier.scopusauthoridWoo, PCY=7201801340en_US
dc.identifier.scopusauthoridChan, FHW=14059603800en_US
dc.identifier.scopusauthoridShea, YF=25951645500en_US
dc.identifier.scopusauthoridLuk, JKH=7006777797en_US
dc.identifier.scopusauthoridHung, IFN=7006103457en_US
dc.identifier.scopusauthoridChan, TC=22960204100en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats